BGPT: Paper Review: Discovery of a Novel Inhibitor of the Protein Tyrosine Phosphatase Shp2

Fuel Your Discoveries

Quick Explanation Copied

Fumosorinone (Fumos) is reported as a Shp2-selective small-molecule inhibitor

Key evidence presented: recombinant PTP inhibition (Shp2 IC50 ~6.31 μM; weaker effects vs several other PTPs), direct binding by SPR (reported Shp2 KD ~40 nM for WT; reduced ~368 nM for Shp2 Y279A), noncompetitive kinetics, and pathway effects in human cells consistent with Shp2 acting upstream of Ras/ERK signaling, plus reduced invasion-associated Src/Paxillin phosphorylation.

Evidence source:

Long Explanation

Paper Review (Rigorous & Skeptical): “Discovery of a Novel Inhibitor of the Protein Tyrosine Phosphatase Shp2”

Primary reference: 10.1038/srep17626 (Scientific Reports, Dec 02 2015)

Overall claim (as stated by authors): Fumosorinone is a potent, reported Shp2 inhibitor with selectivity over several other PTPs, binds directly to Shp2 (SPR), modulates EGF→Ras/ERK signaling (and Gab1–Shp2 association), leaves Ras-independent ERK activation (PMA and oncogenic Ras contexts) largely intact, and correlates with reduced Src/Paxillin phosphorylation and invasion. Source:

Selectivity (In vitro PTP IC50s)

Evidence traceability: The IC50 values shown above are directly taken from the paper’s Table 1.

Direct Binding (SPR KD)

Critical interpretation: The paper uses a single point mutation (Y279A) as mechanistic validation for predicted binding interactions. However, because the authors also state Y279A “did not show any enzyme activity” (reported in Table 1 and kinetic context), there is an intrinsic difficulty in separating “binding-site specificity” from “loss of correct catalytic architecture/structure” effects.

Full-length vs Isolated PTP Domain

Mechanistic claim (as authors frame it): The paper interprets the lower potency against full-length Shp2 as interference from the N-SH2 autoinhibitory interaction with the catalytic domain, suggesting Fumos may preferentially inhibit activated Shp2.

Mechanistic wiring diagram (as proposed)

Important: This is the mechanism diagram as presented/argued by the authors; it is not a fully independent causal proof of direct pathway wiring. The paper’s own discussion notes controversies about the precise Shp2→Ras mechanism.

Skeptical critique: what is strong vs what remains uncertain

Strengths (within what the paper explicitly shows)

Multi-layer target evidence: biochemical inhibition (IC50 panel) + direct binding (SPR KD) + mechanistic mutational association (Y279A binding shift) + cellular pathway modulation consistent with upstream Shp2 control.
Selectivity is empirically addressed at the level of an in vitro PTP panel (though panel size is limited vs the full PTP family).
Pathway specificity logic: authors argue pathway upstream positioning by showing inhibition of EGF-induced ERK/Ras and Gab1–Shp2 association, while not blocking PMA-induced ERK1/2 and not inhibiting ERK activation in constitutively active Ras contexts.

Major uncertainties / red flags (explicitly worth testing later)

Limited assay breadth for selectivity and lack of a wider off-target enzymatic panel.
Y279A is both a binding-importance probe and a catalytic-activity loss probe, complicating interpretation of “binding vs conformational disruption.”
Noncompetitive conclusion is based on Lineweaver–Burk fitting, which can be sensitive to experimental noise and model assumptions.
Cellular readouts are partly correlative for phenotypes like invasion: reduced invasion is paired with signaling changes, but causality is not fully established within the paper’s excerpt.
No in vivo efficacy / PK-Tox validation is shown in the provided full text; translational relevance remains unknown.

Raw extracted quantitative panel (from paper tables/text)

Assay module	Target / condition	Reported metric	Value
In vitro PTP inhibition	Shp2 PTP domain	IC50 (μM)	6.31 ± 0.52
In vitro PTP inhibition	PTP1B	IC50 (μM)	14.04 ± 0.60
In vitro PTP inhibition	TCPTP	IC50 (μM)	29.65 ± 0.42
In vitro PTP inhibition	SHP1	IC50 (μM)	34.70 ± 0.37
In vitro PTP inhibition	Selected other PTPs	IC50 (μM)	> 100 (assay ceiling reported)
In vitro PTP inhibition	Shp2 full-length	IC50 (μM)	26.52 ± 0.37
SPR binding	Shp2 WT	KD (nM)	40
SPR binding	Shp2 Y279A	KD (nM)	368

Source for table values:

Methods clarity & reproducibility assessment (based on provided full text)

Enzyme assay setup is described (buffer composition, pH, substrate pNPP, 96-well format, incubation conditions), which improves reproducibility.
SPR instrument and regeneration protocol are named, supporting technical reproducibility.
Statistics are described (one-way ANOVA + Tukey; p<0.01 threshold), but the excerpt does not show full effect-size reporting for every panel.

Explore further on BGPT

Author Reviews on BGPT

Feedback:

Updated: April 07, 2026